Tests letermovir to prevent cytomegalovirus after stem cell transplant in children
Tests letermovir to prevent cytomegalovirus infection in children after stem cell transplant.
Key facts
- Who runs it
- Children's Oncology Group
- Where
- Aurora, Baltimore, Birmingham, Columbus, Dallas, Detroit, Fort Worth, Grand Rapids, Hershey, Honolulu, Houston, Indianapolis, Iowa City, Jacksonville, Kansas City, Louisville, Madison, Memphis, Miami, Nashville, New Orleans, Oakland, Oklahoma City, Philadelphia, Richmond, Salt Lake City, San Antonio, San Francisco, St Louis, Valhalla, and Wilmington, United StatesSee the 33 sites
- Trial code
- Registry title
- A Study of the Drug Letermovir as Prevention of Cytomegalovirus Infection After Stem Cell Transplant in Pediatric Patients
- Status
- Recruiting
- Phase
- Phase 3
- People taking part
- 105 people, planned
- Started
- 11 Jul 2024
- Expected to end
- 30 Jun 2029
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Biospecimen Collection
- Letermovir
- Record updated
- 6 October 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for children and teenagers aged 2 to under 18 who are about to have a donor stem cell transplant and have had CMV before. They will take letermovir to try to prevent a CMV infection.
- Age
- From 2 years to under 18 years, and weighing at least 6 kg (13 lb).
- Sex
- All sexes can join.
- Disease stage
- A donor (allogeneic) transplant is planned, using bone marrow, blood stem cells or cord blood. Performance status score above 50.
- Earlier treatment
- No donor transplant in the past year. No CMV organ disease in the past 6 months. No other anti-CMV drugs planned during the study.
- Biomarker or test result
- Must be CMV antibody (IgG) positive. Kidney function (eGFR) above 10 mL/min/1.73 m^2 and not on dialysis. Direct bilirubin of 2 mg/dL or less. ALT of 10 times the upper limit of normal (set at 45 U/L) or less.
Main reasons for not taking part
- Cannot take letermovir by mouth, or is allergic to it
- CMV organ disease in the past 6 months (180 days)
- Donor transplant within the past year
- Planned use of other anti-CMV drugs, such as ganciclovir or foscarnet
- Pregnant or breastfeeding
The registry criteria, word for word
Show all 19 criteriaShow less
Who can take part
- >= 2 years and < 18 years at the time of enrollment
- Weight must be >= 6 kg at the time of enrollment
- Planned allogeneic HCT (bone marrow, peripheral blood stem cell, or cord blood transplant)
- Patient must be CMV sero-positive (i.e., recipient CMV immunoglobulin G positive); Note: If a patient has hypogammaglobulinemia but has previously been documented as CMV sero-positive, that is acceptable for study inclusion. For all patients already confirmed to be CMV IgG seropositive, repeat testing is not required within 7 days prior to enrollment. However, the laboratory data determining eligibility must be available in the patient's medical/research record for verification
- Patient is eligible for entry only if it is feasible for plasma CMV PCR testing to be sent and resulted within the protocol mandated time period; Reminder: To limit the likelihood of positive plasma CMV PCR post-enrollment and prior to start of study treatment period, it is recommended that patient enrollment proceed after patients start their transplant preparative regimen
- Patient must have a performance status corresponding to Lansky/Karnofsky scores > 50; Note: Use Lansky for patients =< 16 years of age and Karnofsky for patients > 16 years of age. For further reference, see performance status scales scoring under the standard sections for protocols among protocol reference materials provided on the Children's Oncology Group (COG) member website: https://members.childrensoncologygroup.org/prot/reference_materials.asp
- Estimated glomerular filtration rate > 10 mL/min/1.73 m\^2 and not receiving dialysis
- Direct bilirubin =< 2 mg/dL and serum glutamate-pyruvate transaminase (SPGT) (alanine transaminase [ALT]) =<10 x upper limit of normal (ULN) for age; Note: For the purpose of this study, the ULN for SGPT (ALT) has been set to the value of 45 U/L
Who cannot take part
- History of CMV end organ disease within 6 months (180 days) prior to enrollment; Note: CMV end organ disease based on proposed definitions by Ljungman et al. and inclusive of proven, probable or possible disease
- Receipt of prior allogeneic HCT within one year of study enrollment
- Planned receipt of the following contraindicated medications during the study treatment period; contraindicated medications must be discontinued at least 14 days prior to Day +1; Contraindicated medications for all patients:; Pimozide; Ergot alkaloids; Contraindicated medications for patients planned to receive cyclosporine:; Bosentan; Pitavastatin; Simvastatin
- Hypersensitivity to letermovir or any component of the formulation
- All institutional, Food and Drug Administration (FDA), and National Cancer Institute (NCI) requirements for human studies must be met
- Planned prophylactic administration of other anti-CMV medications or cellular products during the study, including:; High dose acyclovir (defined as doses >= 1500 mg/m\^2 IV or >= 3200 mg oral (patients >= 40 kg) or >= 2400 mg/m\^2 (patients < 40 kg) per day); High dose valacyclovir (defined as doses >= 3000 mg/day in patients > 20 kg); Foscarnet; Ganciclovir; Valganciclovir; CMV-directed cytotoxic T lymphocytes
- Expected inability to tolerate oral formulation of letermovir
- Female patients who are pregnant since fetal toxicities and teratogenic effects have been noted in certain animal reproduction studies with letermovir. A pregnancy test is required for female patients of childbearing potential
- Lactating females who plan to breastfeed their infants
- Sexually active female patients of reproductive potential who have not agreed to use an effective contraceptive method for the duration of their letermovir treatment and through at least 4 weeks after the last dose of letermovir; Note: No contraception measures are needed specifically during letermovir treatment for male trial participants who have pregnant or non-pregnant female partner(s) of reproductive potential. Contraception measures may be required for other aspects of the HCT procedure
- All patients and/or their parents or legal guardians must sign a written informed consent
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 2 and 18 years old?
Where in United States
- Children's Hospital ColoradoAurora, United StatesContact: Sanam Shahid (principal investigator)Taking people
- Johns Hopkins University/Sidney Kimmel Cancer CenterBaltimore, United StatesContact: Heather J. Symons (principal investigator)Taking people
- Children's Hospital of AlabamaBirmingham, United StatesContact: Joseph H. Chewning (principal investigator)Taking people
- Nationwide Children's HospitalColumbus, United StatesContact: Mark A. Ranalli (principal investigator)Taking people
- Medical City Dallas HospitalDallas, United StatesContact: Maurizio L. Ghisoli (principal investigator)Taking people
- UT Southwestern/Simmons Cancer Center-DallasDallas, United StatesContact: Victor M. Aquino (principal investigator)Taking people
- Children's Hospital of MichiganDetroit, United StatesContact: Erin Goode (principal investigator)Taking people
- Cook Children's Medical CenterFort Worth, United StatesContact: Richard P. Howrey (principal investigator)Taking people
- Corewell Health Grand Rapids Hospitals - Helen DeVos Children's HospitalGrand Rapids, United StatesContact: Kathleen Y. Butler (principal investigator)Taking people
- Penn State Children's HospitalHershey, United StatesContact: Lisa M. McGregor (principal investigator)Taking people
- Kapiolani Medical Center for Women and ChildrenHonolulu, United StatesContact: Wade T. Kyono (principal investigator)Taking people
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer CenterHouston, United StatesContact: Anil George (principal investigator)Taking people
- Riley Hospital for ChildrenIndianapolis, United StatesContact: April Rahrig (principal investigator)Taking people
- University of Iowa/Holden Comprehensive Cancer CenterIowa City, United StatesContact: Andrew P. Groves (principal investigator)Taking people
- Nemours Children's Clinic-JacksonvilleJacksonville, United StatesContact: Sridhi Patel (principal investigator)Taking people
- Children's Mercy Hospitals and ClinicsKansas City, United StatesContact: Lauren C. Wilson (principal investigator)Taking people
- Norton Children's HospitalLouisville, United StatesContact: Michael J. Ferguson (principal investigator)Taking people
- University of Wisconsin Carbone Cancer Center - University HospitalMadison, United StatesContact: Christian M. Capitini (principal investigator)Taking people
- Saint Jude Children's Research HospitalMemphis, United StatesNo longer taking part
- Nicklaus Children's HospitalMiami, United StatesContact: Ossama M. Maher (principal investigator)Taking people
- The Children's Hospital at TriStar CentennialNashville, United StatesContact: Clinton M. Carroll (principal investigator)Taking people
- Vanderbilt University/Ingram Cancer CenterNashville, United StatesContact: Carrie L. Kitko (principal investigator)Taking people
- Children's Hospital New OrleansNew Orleans, United StatesContact: Maria C. Velez-Yanguas (principal investigator)Taking people
- UCSF Benioff Children's Hospital OaklandOakland, United StatesContact: Jennifer G. Michlitsch (principal investigator)Taking people
- University of Oklahoma Health Sciences CenterOklahoma City, United StatesContact: Rene Y. McNall-Knapp (principal investigator)Taking people
- Children's Hospital of PhiladelphiaPhiladelphia, United StatesContact: Caitlin W. Elgarten (principal investigator)Taking people
- VCU Massey Comprehensive Cancer CenterRichmond, United StatesContact: Elizabeth Krieger (principal investigator)Taking people
- Primary Children's HospitalSalt Lake City, United StatesContact: Soohee Cho (principal investigator)Taking people
- Methodist Children's Hospital of South TexasSan Antonio, United StatesContact: Jose M. Esquilin (principal investigator)Taking people
- UCSF Medical Center-Mission BaySan Francisco, United StatesContact: Lena E. Winestone (principal investigator)Taking people
- Washington University School of MedicineSt Louis, United StatesContact: Shalini Shenoy (principal investigator)Taking people
- New York Medical CollegeValhalla, United StatesContact: Andrew J. Bellantoni (principal investigator)Taking people
- Alfred I duPont Hospital for ChildrenWilmington, United StatesContact: Sridhi Patel (principal investigator)Taking people
About the trial
What the trial wants to find out
This phase III single arm trial determines whether taking prophylactic letermovir will reduce the likelihood of infection with cytomegalovirus (CMV) in children and adolescents after stem cell transplant compared to estimated rate of infection without prophylaxis. The treatments used to prepare for hematopoietic cell transplant (HCT) reduce the body's natural infection-fighting ability and increase the likelihood of an infection with a virus called cytomegalovirus. "Prophylaxis" means to take a drug to prevent a disease or side effect. Letermovir is an antiviral drug that stops cytomegalovirus from multiplying and may prevent cytomegalovirus infection and make the disease less severe.
The 2 groups in the trial
- ARM A (Letermovir prophylaxis)Treatment being tested
Patients receive letermovir PO or IV over 60 minutes QD starting on day +1 post-transplant for 14 weeks. Patients undergo collection of blood samples for CMV PCR analysis weekly for 14 weeks, every 2 weeks until week 24, week 32, week 40 and week 52.
Treatment: Biospecimen Collection and Letermovir
- Arm B (No prophylaxis)Existing treatment, for comparison
Patients undergo collection of blood samples for CMV PCR analysis weekly for 14 weeks, every 2 weeks until week 24, week 32, week 40 and week 52. (CLOSED TO ACCURAL 09/29/2025)
Treatment: Biospecimen Collection
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Letermovir Prophylaxis for Cytomegalovirus in Pediatric Hematopoietic Cell Transplantation
- Plain-language title
- Tests letermovir to prevent cytomegalovirus after stem cell transplant in childrenGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT05711667, who can take part
- Record updated
- 6 October 2026